Eurofins Expands Its Presence in India with the Acquisition of Spectro Analytical Labs
2017年11月16日 - 3:30PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), a global leader in bioanalytical
testing, announces that it has acquired Spectro Analytical Labs
Ltd. (“Spectro”), a leading environment, analytical product testing
and inspection company in India.
The company has over 22 years of experience in quality testing
and inspection-related services, and owns accreditations from the
National Accreditation Board for Testing and Calibration
Laboratories (NABL) in six fields: Chemical, Mechanical, Biology,
Non-destructive Testing, Calibration and Electrical and
Electronics. Starting from a small facility in New Delhi, Spectro
has steadily achieved strong growth to become India’s leading
environment and analytical laboratory with operations and joint
ventures all over the country, catering to more than 8,000
customers. The company operates 5 state-of-the-art laboratories in
India, with a total surface area of ca. 10,000 m2, and employs
close to 450 staff.
The acquisition of Spectro will enable Eurofins to have a strong
environment and analytical testing market entry in India and
significantly increase Eurofins’ market position in this
geographical region.
Comment from Mr. Kuldeep Dhingra, Spectro’s Managing
Director: “We are delighted to become part of the Eurofins Group.
We see tremendous growth opportunities in the Indian testing and
inspection industry and are excited with the prospects of
significant value creation for our clients and employees through
access to Eurofins’ global network of laboratories, technical and
financial competencies.”
Comment from Dr. Gilles Martin, Eurofins’ CEO: “We
are pleased to welcome Spectro, a prominent Indian testing services
provider, to Eurofins’ family of businesses. Spectro’s broad range
of testing and inspection services, combined with Advinus’
biopharmaceutical and agro sciences competencies that were acquired
earlier this year and Eurofins’ existing genomics, food and
clinical testing laboratories, will complement the Group’s
analytical services portfolio and provide Eurofins with a
well-balanced initial market presence in India. This transaction is
another demonstration of Eurofins’ commitment to expand its global
network of analytical services laboratories across all geographical
regions where it anticipates significant growth.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 30,000
staff in 400 laboratories across 41 countries, Eurofins offers a
portfolio of over 150,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171115006364/en/
Eurofins ScientificInvestor Relations+32 2 766
1620ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 9 2024 まで 10 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 10 2023 まで 10 2024